Chronic Kidney Disease

The AJMC® Chronic Kidney Disease compendium is a comprehensive resource for clinical news and expert insights on the condition and treatment of loss of kidney function.

Latest News
December 17th 2024

A Standardized Care Pathway Increases Optimal Dialysis Starts

December 12th 2024

Transforming Kidney Care: Policy, Risk Stratification, and Collaborative Models

October 19th 2024

Fostering Interdisciplinary Communication: How Cardio-Renal-Metabolic Care Models Optimize Care Delivery

October 18th 2024

Population Health Strategies Are Vital for Tackling, Improving CKD Care

October 17th 2024

Long-Term Benefits Show the Value of Upfront Investments in Value-Based Care

Population Health Management of Chronic Kidney Disease (CKD)

An expert panel discusses chronic kidney disease (CKD), its impact on cardiovascular disease, and the methods of treatment used on the patient populations.

Panel members
Video Series
View All
October 15th 2021

Results From the STEP Trial in China

October 15th 2021

Unmet Needs in the Management of Heart Failure

October 8th 2021

Results From the EMPEROR-Pooled Analysis

October 8th 2021

Results From EMPEROR-Preserved: CV Outcomes in Patients With HFpEF

October 1st 2021

Results From FIGARO-DKD and FIDELITY: Finerenone + SGLT2 Inhibitors

October 1st 2021

Practical Implications of the FIDELITY Pooled Analysis

September 24th 2021

Results From the FIDELITY Pooled Analysis

September 24th 2021

An Overview of the FIDELITY Pooled Analysis Design

September 17th 2021

Results From FIGARO-DKD: Finerenone’s Impact on Type 2 Diabetes and CKD

September 17th 2021

An Overview of the FIGARO-DKD Trial Design

Video Interviews
View All
September 4th 2024

UPMC's Dr Manisha Jhamb Urges Better Kidney Disease Awareness, Integrated Care

September 13th 2023

Current Status of Chronic Kidney Disease in the US

September 13th 2023

Navigating CKD Treatment Among Comorbidities

January 22nd 2023

Dr Kirsten Johansen on Benefits of Oral Therapies for the Management of CKD

November 26th 2022

Empagliflozin Has Similar Efficacy Across Subgroups, More Data Needed in CKD: Dr Jennifer Green

October 5th 2022

Closing Thoughts on CKD Management

October 5th 2022

Continued Health Disparities Seen in Practice

September 28th 2022

Combination Therapy and Payer Perspective on CKD Therapies

September 28th 2022

Using Published Data to Consider SGLT2 Inhibitors and MRAs in CKD Management

September 21st 2022

The Role of MRAs in CKD and CV Treatment

Podcasts
View All
October 22nd 2024

Engage, Educate, Empower: Transforming Kidney Care

March 24th 2023

More Needs to Be Done to Reduce Racial Disparities in Home Dialysis

April 26th 2022

Advocating for All Patients With Chronic Kidney Disease

November 9th 2021

Managing Disparities in Chronic Kidney Disease Through Value-Based Arrangements

January 12th 2021

Examining the Shift to Value-Based Kidney Care Delivery in 2021

More News

kidneys and stethoscope | Image Credit: © filins - stock.adpbe.com
December 10th 2024

Dallas Nephrology Associates’ Journey to Value-Based Care

Belinda Tommey, MHA Paul Skluzacek, MD Melissa Echols, BSN LeAnn Phelps, MSN Mollyn Shew Alexander Liang, MD
Preventing or delaying the onset of end-stage kidney disease is vital. By implementing a results-driven, value-based approach, Dallas Nephrology Associates has demonstrated improved patient outcomes and value for payers.
AJMC
June 24th 2024

Identifying Chronic Kidney Disease Stage 3 With Excess Disease Burden

Austin Campbell, PhD Lihao Chu, PhD Stanley Crittenden, MD Abe Sutton, JD Adam Boehler, BS
A high-risk cohort of beneficiaries with chronic kidney disease (CKD) stage 3 have a profile similar to patients with CKD stages 4 and 5, indicating potential benefit of earlier nephrology intervention.
Kidney and stethoscope lies on a blue background | Image Credit: © filins - stock.adobe.com
June 10th 2024

Leveraging Patient Activation to Improve Kidney Health in High-Risk Patients

Shanoor N. Seervai, MPP Elizabeth Montgomery, BS Hilary Hatch, PhD Kelsey Jones Pratt, MPA Jai Seth, MSc Stella E. Sechopoulos, BA Judith H. Hibbard, DrPH
Frequency of patient-provider conversations and patient activation are the 2 most significant predictors of a high-risk patient’s behaviors to prevent kidney disease.
AJMC
May 13th 2024

Defragmentation of Care in Complex Patients With ESKD Improves Clinical Outcomes

Nathan Moore, MD David Roer, MD
A novel program utilizing an approach to defragment care for patients with end-stage kidney disease (ESKD) resulted in better patient outcomes.
FDA Approval. | Image Credit: Looker_Studio - stock.adobe.com
March 28th 2024

FDA Approves Vadadustat for Anemia in Patients With CKD Undergoing Dialysis

Cameron Santoro
The FDA approved vadadustat (Vafseo), an oral medication, to treat anemia in adult patients with chronic kidney disease (CKD) on dialysis for at least 3 months. This fills a need for a new treatment option as anemia is common in these patients and can significantly impact their quality of life.
Madeleine McDowell, MD | Image Credit: LinkedIn
October 6th 2023

Dr Madeleine McDowell: CKD Hits Harder and Earlier in Socially Challenged Neighborhoods

Giuliana Grossi
The data show the average age of dialysis in the least vulnerable neighborhoods was 68.2 years old, but 59.4 years—almost a decade earlier—in the most vulnerable.
Madeleine McDowell, MD | Image Credit: LinkedIn
October 4th 2023

Dr Madeleine McDowell Discusses How CKD Disparities, Social Challenges Impact Health Care Access

Giuliana Grossi
Madeleine McDowell, MD, hopes these data insights will help change providers' behavior in terms of adopting earlier and more regular screening for chronic kidney disease (CKD).
AJMC
September 18th 2023

Predicting Hospitalizations for Patients With Chronic Kidney Disease

Steph Karpinski, MS Scott Sibbel, PhD, MPH Kathryn Gray, MA Adam G. Walker, PhD Jiacong Luo, MD Carey Colson, MBA Juliana Stebbins, MPH Steven M. Brunelli, MD, MSCE
The authors developed an algorithm that uses medical claims to identify patients with chronic kidney disease who are at greatest risk of being hospitalized within 90 days.
[Nurse recording dialysis] Credit: iStock
September 8th 2023

Contributor: Medicare Policy Proposal Jeopardizes Care for Those on Dialysis

LaVarne A. Burton Hrant Jamgochian Lori Hartwell
CEOs of 3 kidney care organizations explain flaws in CMS' recent reimbursement proposal.
Site Logo
March 17th 2023

Have Racial Disparities in Home Dialysis Utilization Changed Over Time?

Virginia Wang, PhD Lindsay Zepel, MS Cynthia J. Coffman, PhD Clarissa J. Diamantidis, MD, MHS Sarah Hudson Scholle, DrPH, MPH Matthew L. Maciejewski, PhD
Medicare prospective payment for dialysis modestly increased availability and use of home-based dialysis treatment but did not affect historic racial disparities in home dialysis.
Site Logo
February 16th 2023

Health Care Costs Associated With Unrecognized Progression to Late-Stage Kidney Disease

Donna Spencer, PhD Stephan Dunning, MBA Jeff McPheeters, BA Jennifer St. Clair Russell, PhD, MSEd, MCHES Christopher Hane, PhD
Unrecognized disease progression is associated with higher health care costs both for patients with end-stage kidney disease and late-stage (stages G4-G5) chronic kidney disease.
Site Logo
February 14th 2023

Transition-to-Dialysis Planning, Health Care Use, and Mortality in End-Stage Renal Disease

Insiya Poonawalla, PhD, MS Kanchan Barve, MS, MBA Meghan Cockrell, MPH Amal Agarwal, DO, MBA Adrianne W. Casebeer, PhD, MS, MPP Suzanne W. Dixon, MPH, MS, RDN Yong Li, PhD
A planned transition to dialysis was associated with improved outcomes and lower mortality. These findings may inform care coordination policies for end-stage renal disease.
Black male patient.
February 7th 2023

Bloodstream Infection Risk Associated With Race, SES Among Patients on Hemodialysis

Matthew Gavidia
Data released in the CDC’s latest Morbidity and Mortality Weekly Report indicate that patients with end-stage kidney disease on hemodialysis who are Black, Hispanic/Latino, or of lower socioeconomic status (SES) are at greater risk of Staphylococcus aureus bloodstream infections, with Hispanic/Latino ethnicity cited as an independent risk factor.
white FDA logo on blue background
February 7th 2023

FDA Approves Daprodustat for Anemia From CKD in Adult Dialysis Patients

Daprodustat (Jesduvroq, GSK) is the first oral hypoxia-inducible factor prolyl hydroxylase inhibitor to gain approval in the United States.
The Top 5 CKD Articles of 2022
December 27th 2022

Top 5 Most-Read CKD Content of 2022

Julia Bonavitacola
The top 5 most-read articles about chronic kidney disease (CKD) focused on finerenone benefits, anticoagulants, dementia association, and more.
Kidneys
December 23rd 2022

ICYMI: Top Content From Kidney Week 2022

Julia Bonavitacola
Kidney Week 2022 focused on effectiveness of treatment for chronic kidney disease, health misinformation, and outcomes in chronic kidney disease, among other topics.
Kidneys
December 22nd 2022

Kidney Tubular Secretion Associated With Faster eGFR Decline

Julia Bonavitacola
Lower estimated tubular secretion was found to be associated with a faster decline of estimated glomerular filtration rate (eGFR) but wasn’t associated with progression of chronic kidney disease or cardiovascular disease.
Kidneys
December 19th 2022

Oral Roxadustat Improved Hemoglobin Levels in Patients With CKD

Julia Bonavitacola
A retrospective study found roxadustat to be more effective in improving hemoglobin levels in patients who had with chronic kidney disease (CKD) compared with recombinant human erythropoietin.
Kidneys with heart in the background
December 15th 2022

ICD Implantation Associated With Lower Risk of Mortality in Patients With CKD

Julia Bonavitacola
Implantable cardioverter defibrillators (ICDs) were found to have a beneficial effect on mortality in patients with chronic kidney disease (CKD).
Doctor holding model of kidney
December 13th 2022

DOAC Prescriptions Gradually Displaced Warfarin in AF, CKD Treatment

Julia Bonavitacola
Prescriptions for treatment of atrial fibrillation (AF) and chronic kidney disease (CKD) have primarily been prescriptions for direct oral anticoagulants (DOACs), displacing warfarin as the primary treatment.
Kidneys
December 9th 2022

CKD Associated With Abdominal Aortic Aneurysm

Julia Bonavitacola
A cohort study found that chronic kidney disease (CKD) was associated with the development of abdominal aortic aneurysm, with risk increasing as CKD stage advanced.
Kidneys
December 7th 2022

Patients With CKD Report Burden Could Improve Through Communication With Physicians

Julia Bonavitacola
Speaking with patients diagnosed with chronic kidney disease (CKD) about the burdens associated with care could help improve understanding of the disease and their communication with health care professionals.
Kidneys
December 1st 2022

Kidney Failure–Free Survival Increased With ACE, SGLT2 Inhibitors

Julia Bonavitacola
Treatment with an angiotensin-converting enzyme (ACE) inhibitor/angiotensin receptor blocker and sodium-glucose cotransporter-2 (SGLT2) inhibitor combination demonstrated better outcomes in kidney failure.
Kidneys
November 29th 2022

Nonalcoholic Fatty Liver Disease Related to Increased Incidence of CKD

Julia Bonavitacola
A new review has found that increased incidence of chronic kidney disease (CKD) may be seen among patients with nonalcoholic fatty liver disease.
patient and caregiver
November 23rd 2022

Examining the Impact of CKD on Individuals, Caregivers

AJMC Staff
The studies reviewed estimates of economic and humanistic impact on both patients with chronic kidney disease (CKD) as well as their caregivers.
Image of kidneys
November 21st 2022

New Clinical Guidelines Recommend Finerenone for CKD Associated With T2D

Rose McNulty
Updated Kidney Disease: Improving Global Outcomes guidelines and a consensus report with the American Diabetes Association support the use of finerenone in certain patients who have chronic kidney disease (CKD) that may be linked to type 2 diabetes (T2D).
What We're Reading
November 17th 2022

What We’re Reading: Tenapanor Recommended for Dialysis; Home Births Up During Pandemic; Call for RSV, Flu Emergency

AJMC Staff
FDA advisers voted in favor of approving Ardelyx’s tenapanor for patients with chronic kidney disease on dialysis; US home births increased by about 12% between 2020 and 2021; surges in respiratory viruses, especially respiratory syncytial virus (RSV) among younger children are putting pediatric hospitals at capacity.
Kidney
November 3rd 2022

Glomerular Filtration Rate Based on Cystatin C More Accurate for Predicting CVD, Mortality

Julia Bonavitacola
A prospective population-based cohort study found that glomerular filtration rate based on cystatin C was more sensitive and specific for cardiovascular disease (CVD) and mortality risks compared with glomerular filtration rate based on creatinine.
Removal of Race Adjustment Improved Bias, Accuracy in eGFR Equations for Black Adults
October 31st 2022

Removal of Race Adjustment Improved Bias, Accuracy in eGFR Equations for Black Adults

Julia Bonavitacola
A systematic review found that alternative approaches to calculating estimated glomerular filtration rate (eGFR) were worth looking into to properly account for diversity in populations.
Julianne Malveaux, PhD
October 23rd 2022

Contributor: Congress Must Fix Patient Protection Statute Upended by Supreme Court

Julianne Malveaux, PhD
The author, the dean of the College of Ethnic Studies at California State University Los Angeles, says a Supreme Court ruling could upend insurance protections for patients with kidney diseases, disproportionately hurting those who are Black, Hispanic, Asian, and other diverse ethnicities.
12345678
...
12>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo